Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 8/20 | 0.36 |
| ▸ | DRD1 | P21728 | 8/20 | 0.36 |
| ▸ | DRD4 | P21917 | 8/20 | 0.36 |
| ▸ | HTR2A | P28223 | 8/20 | 0.36 |
| ▸ | DRD3 | P35462 | 8/20 | 0.36 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3763690 | 0.91 | PIK3CA (0.40) | PIK3CAPIK3CDPIK3CBERN1CYP2A6 | |
| SCHEMBL3645750 | 0.91 | PIK3CA (0.40) | PIK3CAPIK3CDPIK3CBERN1DRD2 | |
| SCHEMBL3076808 | 0.79 | DRD2 (0.36) | PIK3CAPIK3CDPIK3CBDRD2DRD1 | |
| SCHEMBL3065072 | 0.79 | HTR2A (0.39) | PIK3CAPIK3CDPIK3CBERN1DRD2 | |
| SCHEMBL3073487 | 0.79 | PIK3CA (0.43) | PIK3CAPIK3CDPIK3CBDRD2DRD1 | |
| SCHEMBL31595984 | 0.79 | PIK3CA (0.38) | PIK3CAPIK3CDPIK3CBDRD2DRD1 | |
| SCHEMBL3078971 | 0.79 | PIK3CA (0.42) | PIK3CAPIK3CDPIK3CBERN1DRD2 | |
| SCHEMBL3075903 | 0.79 | EPHB3 (0.44) | PIK3CAPIK3CDPIK3CBERN1DRD2 | |
| SCHEMBL15952155 | 0.79 | PIK3CD (0.44) | PIK3CAPIK3CDPIK3CBDRD2DRD1 | |
| SCHEMBL15952156 | 0.79 | PIK3CD (0.44) | PIK3CAPIK3CDPIK3CBDRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| CN-115181092-B | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-116332937-A | Dipeptidyl peptidase I inhibitors and uses thereof | 杭州邦顺制药有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2023-06-01 | — | — | US | disclosed |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-11571420-B2 | Pyrazine compounds and uses thereof | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-02-07 | — | — | US | disclosed |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| US-10898481-B2 | Pyrazine compounds and uses thereof | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-01-26 | — | — | US | disclosed |
| US-9573953-B2 | Heteroaromatic compounds as PI3 kinase modulators and methods of use | CALITOR SCIENCES, LLC (US) | 2017-02-21 | — | — | US | disclosed |
| EP-2958564-A1 | HETEROAROMATIC COMPOUNDS AS PI3 KINASE MODULATORS | Calitor Sciences, LLC (US) | 2015-12-30 | — | — | EP | disclosed |
| WO-2014130375-A1 | HETEROAROMATIC COMPOUNDS AS PI3 KINASE MODULATORS | CALITOR SCIENCES, LLC (US) | 2014-08-28 | — | — | WO | disclosed |
| US-20140234254-A1 | HETEROAROMATIC COMPOUNDS AS PI3 KINASE MODULATORS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-08-21 | — | — | US | disclosed |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-09 | — | — | US | disclosed |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-09 | — | — | US | disclosed |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-09 | — | — | US | disclosed |
| EP-2176260-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009008748-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009008748-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10898481-B2 | Pyrazine compounds and uses thereof | ADORA2A, ADORA2B, ADORA1 | PIK3CA 161/4885PIK3CD 393/4885PIK3CB 301/4885 |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | PIK3CA 161/4885PIK3CD 393/4885PIK3CB 301/4885 |
| US-11571420-B2 | Pyrazine compounds and uses thereof | ADORA2A, ADORA2B, ADORA1 | PIK3CA 161/4885PIK3CD 393/4885PIK3CB 301/4885 |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | TP53, PNPO, DPYD | PIK3CA 410/4885PIK3CD 1820/4885PIK3CB 1107/4885 |
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | PIK3CA 401/4885PIK3CD 1356/4885PIK3CB 1160/4885 |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | PIK3CA 161/4885PIK3CD 393/4885PIK3CB 301/4885 |
| US-20140234254-A1 | HETEROAROMATIC COMPOUNDS AS PI3 KINASE MODULATORS AND METHODS OF USE | PIK3R1, PIK3R3, AKT3 | PIK3CA 5/4885PIK3CD 4/4885PIK3CB 16/4885 |
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | PIK3CA 3008/4885PIK3CD 4599/4885PIK3CB 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.